Apollomics, Inc. Announces Initiation of SPARTA Phase 2 Clinical Trial for c-MET Inhibitor APL-101
– Trial will evaluate diverse MET dysregulations across broad tumor types – – Focus on non-small cell lung cancer with a mutation that leads to MET exon 14 skipping, and tumors with amplifications and MET fusions, including glioblastoma multiforme – Foster City, CA, and Hangzhou, China, 21 May 2020 — Apollomics, Inc., an innovative biopharmaceutical company […]
